NUS Links:
We are pleased to share that Prof. Goh Boon Cher and A/Prof. Wang Lingzhi have published a new edited volume with World Scientific titled Organoids: Advancements in Drug Discovery and Precision
Acute myeloid leukaemia (AML) is a fast-growing blood cancer that often becomes resistant to standard treatments. This resistance is linked to proteins that prevent cancer cells from dying. A new
Treatment of relapsed/refractory non-Hodgkin’s lymphoma (R/R-NHL) remains one of the most difficult challenges in haematologic malignancies, with many patients exhausting standard therapies and facing limited treatment options. In a final
Sorafenib is a first-line therapy used to treat advanced liver cancer, but its effectiveness is often reduced due to resistance in cancer cells. This study co-led by N2CR member, A/Prof
Venetoclax (VEN) is a targeted therapy used to treat chronic lymphocytic leukemia and acute myeloid leukemia. It works by blocking Bcl-2, a protein that prevents cells from undergoing programmed cell
A Phase I clinical trial, led by N2CR clinician-scientist A/Prof David Tan, tested a new drug combination—Selinexor, nivolumab (NIVO), and ipilimumab (IPI)—in Asian patients with advanced solid tumours/cancers and had
Multiple myeloma (MM) is a type of blood cancer that originates from abnormal plasma cells in the bone marrow, leading to serious complications such as bone damage, anaemia, kidney dysfunction,
Multiple primary cancers (MPC) often indicate a hereditary cancer predisposition syndrome. In a study led by Prof Lee Soo Chin, 19% of 3514 cancer patients who underwent germline genetic testing
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow, leading to the buildup of abnormal lymphocytes. It is the most common form of
Muscle is our first line of defence against cancer. A randomised clinical trial in Singapore, led by N2CR members A/Prof Alfredo Franco-Obregon & Dr Alex Tai Yee Kit, with N2CR